Dr Lal PathLabs Q1 FY27 results: July 24 watchpoints

Key date on the calendar

Dr Lal PathLabs Ltd is scheduled to announce its Q1 FY2026-27 results on July 24, 2026. The company has said its Board of Directors will meet on July 24, 2026 to consider and approve the unaudited financial results for the quarter ended June 30, 2026. For investors, this is the first formal read on how the new financial year has begun, especially on volumes and margins.

The last reported earnings date in the provided information is Q4 FY2025-26 on April 30, 2026. The Q4 print matters because it included the company’s strongest year-on-year growth performance within FY26, setting a high base for comparisons.

Quick snapshot: company and market metrics shown

The dataset shared alongside the results calendar lists key reference points that investors often use around earnings. These include market cap of Rs 28,287.2 crore and a current market price (CMP) of Rs 1,687.4. It also cites the previous quarter numbers as revenue of Rs 702.7 crore and profit after tax (PAT) of Rs 131.3 crore.

Separately, an earnings dashboard summary included in the text shows: Revenue 702 (crore) with QoQ growth of 6.50% and YoY growth of 16.61%; Net Profit 132 (crore) with QoQ change of 44.64% and YoY change of -14.98%.

What the company delivered in Q4 FY26

In the quarter ended March 2026 (Q4 FY26), the company’s earnings presentation states that revenue reached Rs 703 crore, up from Rs 603 crore in Q4 FY25, implying 16.6% YoY growth. The same presentation shows EBITDA before exceptional items of Rs 187 crore in Q4 FY26 versus Rs 169 crore in Q4 FY25, and PAT before exceptional items of Rs 132 crore versus Rs 115 crore.

Operationally, the presentation highlights volume growth as a key driver. It reports samples of 7.4 million in Q4 FY26 compared with 6.8 million in Q4 FY25, and patients of 23.6 million versus 20.9 million.

Margin discussion: guidance versus reported trend

The same context also points to a margin debate going into Q1. Management guidance referenced in the text indicates an EBITDA margin range of 27%-28% for FY27. This guidance follows an EBITDA margin of 26.6% in Q4 FY26 and 28.32% for the full FY26 year.

A brokerage-style note included in the text adds that Q4 FY26 EBITDA margin was 26.6%, described as weaker due to network expansion and promotional costs. It also states gross margin expanded to 80.8% in Q4 FY26, while EBITDA margin contracted on higher promotion and marketing expenses.

Costs and network expansion remain in focus

The information provided flags operating cost lines that investors may track in the upcoming quarter. It says operating expenses, particularly franchisee and collection-centre fees, are expected to remain elevated as a percentage of revenue after the addition of 600-800 collection centres during FY26.

On input costs, it states that the cost of materials consumed remained steady at 19.2% of revenue in Q4 FY26, consistent with the Q1 FY26 level. It also notes that no changes in customs duty on reagents were enacted during Q1 FY27 that would alter this cost profile.

Seasonality and the specific Q1 questions

The text explicitly notes that Q1 is seasonally the weakest period for diagnostic volumes. Against that backdrop, it says the company benefits from a low base of 11.3% growth in the year-ago quarter.

For the July 24 results call, the text says attention will be on realisation per test and the impact of monsoon-related acute test volumes. These operating metrics often explain quarter-to-quarter revenue quality beyond headline growth.

Conference call: time and access details

Dr Lal PathLabs will host a conference call on Friday, July 24, 2026 at 5:30 PM IST after the results, according to the details provided. The call is expected to include a management presentation followed by Q&A.

The call is listed as being led by (Hony) Brig. Dr. Arvind Lal (Executive Chairman), Mr. Shankha Banerjee (Chief Executive Officer), and Mr. Ved Prakash Goel (Group Chief Financial Officer and CEO – International Business). The dial-in details in the text include Universal Access: +91 22 6280 1141, +91 22 7115 8042, and international access numbers for the USA, UK, Singapore, and Hong Kong.

Selected numbers mentioned in the provided data

Why July 24 matters for investors

The near-term market relevance is straightforward: July 24 brings the first official read on whether strong FY26 exit momentum carries into a seasonally softer quarter, and how costs behave after a year of collection-centre additions. The margin frame is also clearly laid out in the provided text: management has guided 27%-28% EBITDA margin, while Q4 FY26 stood at 26.6%.

The earnings call structure and named leadership team also indicate that the company intends to discuss both financial metrics and operating performance, with Q&A for investor queries. With costs such as franchisee and collection-centre fees highlighted as elevated, and realisation per test flagged as a focus area, the July 24 interaction is likely to be closely tracked for data points that the company itself has identified.

Conclusion

Dr Lal PathLabs’ July 24, 2026 board meeting and results announcement sets up a key checkpoint after Q4 FY26 revenue of about Rs 703 crore and PAT of about Rs 132 crore, alongside an FY27 EBITDA margin guidance of 27%-28%. The company’s scheduled 5:30 PM IST conference call will be the next confirmed forum for management commentary on operating metrics, realisations, seasonality, and cost trends.